July  31, 2015 – We are pleased to announce we have begun a fundraiser through Maximum Life Foundation (“MaxLife”) to use a promising gene therapy to treat patients with Alzheimer’s Disease (AD) and find a cure. MaxLife will grant 100% of the money raised to BioViva to help bring pioneering gene therapy to cure this disease and make Alzheimer’s a thing of the past. 

Despite years of research and billions of dollars spent, there is still no cure for AD and there are multiple negative side effects of approved medications on the market. Many current approaches focus on the consequences alone but BioViva’s gene therapy could offer a cure, halting the disease by rejuvenating microglial cells, which are the brain’s first line of defense against infection. Improvements of AD symptoms, and the recovery of normal brain functions has been demonstrated in-vivo in mouse experiments, and in-vitro in human cell experiments through the rejuvenation of microglia and neurons using the telomerase reverse transcriptase (TERT) protein. In these experiments the TERT protein colocaliszes with mitochondria to protect against oxidative damage. Additionally, cells with TERT protein expression did not contain hyperphosphorylated tau which are protein aggregates responsible for exacerbating Alzheimer's. 

In recent studies, Alzheimer's symptoms were found in brain images in people as young as 20. By the time of diagnosis up to 40% of the brain can be damaged. “If we can prove a benefit to patients that have no other option now, we can potentially treat Alzheimer’s disease in people before these symptoms arise, creating real preventative medicine at the cellular level,” states BioViva’s CEO Elizabeth Parrish. “If successful this treatment could potentially be used on other similar diseases such as Parkinson’s and ALS in the future to treat some of the worst diseases on the planet”.

BioViva’s unique approach is treating the cellular degeneration caused by aging as the root cause of most major diseases, indeed studies have proven aging is the leading risk factor for many life threatening diseases including Alzheimer's. “This technology has the ability to reverse the age related dysfunction in cells and tissues and the damage it causes, this could halt many of the big age associated killers in industrialized countries’” states Elizabeth Parrish. Compassionate care helps patients with no other option get access to experimental therapies that may benefit both themselves and society as a whole. 

Alzheimer's not only effects those suffering with it but it touches the lives of loved ones, family, friends and carers. We believe it is time to to end the suffering and with your help we can do this, please consider helping us reach our goal of getting breakthrough medicine tested now so we can make Alzheimer's a thing of the past. Together we can do this!

Please visit MaxLife Foundation to learn more about our project.